Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Consensus Target Price from Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $29.17.

Several equities analysts have issued reports on CELC shares. Lifesci Capital initiated coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target for the company. Stifel Nicolaus increased their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Celcuity in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th.

Celcuity Stock Performance

Celcuity stock opened at $12.46 on Friday. The business has a 50 day moving average of $14.08 and a 200-day moving average of $15.39. The company has a market capitalization of $462.64 million, a P/E ratio of -4.77 and a beta of 0.74. Celcuity has a 1 year low of $11.51 and a 1 year high of $22.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CELC. Quest Partners LLC increased its holdings in Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after purchasing an additional 1,379 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after acquiring an additional 1,500 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after acquiring an additional 1,600 shares during the period. Acuta Capital Partners LLC lifted its position in shares of Celcuity by 3.6% during the 3rd quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after acquiring an additional 1,600 shares during the period. Finally, nVerses Capital LLC acquired a new stake in Celcuity in the third quarter worth $33,000. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.